Literature DB >> 32454781

Comparative In Vitro and In Vivo Evaluation of Fenofibric Acid as an Antihyperlipidemic Drug.

Yulias Ninik Windriyati1,2, Yeyet Cahyati Sumirtapura1, Jessie Sofia Pamudji1.   

Abstract

OBJECTIVES: Fenofibric acid (FA) is antihyperlipidemic agent and commercially available as a tablet formulation that weighs 840 mg for 105 mg of active substance. A new formulation with less inactive substance was developed as an alternative to the conventional formulation. The purpose of this study was to evaluate the dissolution and the relative bioavailability of the surface solid dispersion (SSD) and conventional formulations of FA by comparing them with the reference formulation in its commercial tablets. The in vitro-in vivo correlation among these tablet formulations was also evaluated.
MATERIALS AND METHODS: The dissolution study was performed in phosphate buffer pH 6.8 and biorelevant fasted state simulated intestinal fluid. Dissolution efficiency and mean dissolution time (MDT) were used to compare the dissolution profiles. The bioavailability study, using nine healthy volunteers, was conducted based on a single-dose, fasted, randomized, crossover design. The in vivo performance was compared using the pharmacokinetic parameters Cmax, Tmax, AUC0-72, and AUC0-∞. A linear correlation model was tested using MDT and mean residence time (MRT).
RESULTS: The results indicated that there were significant differences in the dissolution performances but no significant differences among the mean Cmax, Tmax, AUC0-72, or AUC0-∞ estimated from the SSD, conventional, and reference formulations. A poor correlation was found between MRT and MDT of the three formulations.
CONCLUSION: The SSD formulation led to an instantaneous dissolution of the drug due to the presence of the polymer and the physical structure of the SSD. The conventional formulation could not achieve rapid dissolution despite its satisfying the requirement for immediate drug release dosage form. Both formulations could be considered bioequivalent with the reference. The in vitro dissolution behavior of FA using a single medium did not reflect their in vivo properties in the fasted condition. There was no correlation between the in vitro dissolution and the in vivo bioavailability of FA in this condition. ©Copyright 2020 Turk J Pharm Sci, Published by Galenos Publishing House.

Entities:  

Keywords:  Fenofibric acid; bioavailability; correlation; dissolution; surface solid dispersion

Year:  2020        PMID: 32454781      PMCID: PMC7227912          DOI: 10.4274/tjps.galenos.2019.27147

Source DB:  PubMed          Journal:  Turk J Pharm Sci        ISSN: 1304-530X


  12 in total

Review 1.  Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.

Authors:  Gillian M Keating; Katherine F Croom
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans.

Authors:  Tong Zhu; Jean-Claude Ansquer; Maureen T Kelly; Darryl J Sleep; Rajendra S Pradhan
Journal:  J Clin Pharmacol       Date:  2010-02-09       Impact factor: 3.126

3.  Novel fenofibric acid-loaded controlled release pellet bioequivalent to choline fenofibrate-loaded commercial product in beagle dogs.

Authors:  Kyung Soo Kim; Sung Giu Jin; Omer Mustapha; Abid Mehmood Yousaf; Dong Wuk Kim; Young Hun Kim; Jong Oh Kim; Chul Soon Yong; Jong Soo Woo; Han-Gon Choi
Journal:  Int J Pharm       Date:  2015-05-27       Impact factor: 5.875

4.  Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.

Authors:  Anthony R Godfrey; Jennifer Digiacinto; Matthew W Davis
Journal:  Clin Ther       Date:  2011-06       Impact factor: 3.393

5.  Absolute oral bioavailability of fenofibric acid and choline fenofibrate in rats determined by ultra-performance liquid chromatography tandem mass spectrometry.

Authors:  Xudan Wei; Ping Li; Meina Liu; Yuqian Du; Menglin Wang; Jinling Zhang; Jing Wang; Hongzhuo Liu; Xiaohong Liu
Journal:  Biomed Chromatogr       Date:  2016-10-10       Impact factor: 1.902

6.  The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.

Authors:  Yasuhiro Tsume; Deanna M Mudie; Peter Langguth; Greg E Amidon; Gordon L Amidon
Journal:  Eur J Pharm Sci       Date:  2014-01-28       Impact factor: 4.384

7.  The conflict between in vitro release studies in human biorelevant media and the in vivo exposure in rats of the lipophilic compound fenofibrate.

Authors:  Thao Thi Do; Michiel Van Speybroeck; Raf Mols; Pieter Annaert; Johan Martens; Jan Van Humbeeck; Jan Vermant; Patrick Augustijns; Guy Van den Mooter
Journal:  Int J Pharm       Date:  2011-05-07       Impact factor: 5.875

Review 8.  Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia.

Authors:  Peter Alagona
Journal:  Vasc Health Risk Manag       Date:  2010-05-25

9.  Effect of magnesium carbonate on the solubility, dissolution and oral bioavailability of fenofibric acid powder as an alkalising solubilizer.

Authors:  Kyeong Soo Kim; Jeong Hyun Kim; Sung Giu Jin; Dong Wuk Kim; Dong Shik Kim; Jong Oh Kim; Chul Soon Yong; Kwan Hyung Cho; Dong Xun Li; Jong Soo Woo; Han-Gon Choi
Journal:  Arch Pharm Res       Date:  2016-03-18       Impact factor: 4.946

Review 10.  A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations.

Authors:  Hua Ling; John T Luoma; Daniel Hilleman
Journal:  Cardiol Res       Date:  2013-05-09
View more
  1 in total

1.  Comparative Bioavailability Study of Solid Self-Nanoemulsifying Drug Delivery System of Fenofibric Acid in Healthy Male Subjects.

Authors:  Wira Noviana Suhery; Diky Mudhakir; Yeyet Cahyati Sumirtapura; Jessie Sofia Pamudji
Journal:  Med Princ Pract       Date:  2022-02-08       Impact factor: 2.132

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.